MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,705,144
Unit: Dollar
Positive Cash Flow Breakdown
Non-cash operating lease cost
Stock-based compensation expense
Fair value of shares issued for ...
Others
Negative Cash Flow Breakdown
Net loss
Other prepaid expenses
Accounts payable and accrued exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-1,987,608
-6,009,520
-
-
Research and development costs
-
-
-
0
Net loss
-
-
-1,980,398
-1,485,228
Non-cash lease expense for right-of-use asset
-
61,695
-
-
Non-cash operating lease cost
122,553
-
-
-
General and administrative costs
-
-
776,611
367,737
Stock-based compensation expense
82,176
1,388,322
-
-
Common stock issued for services
-
126,900
44,711
-
Unrealized gain (loss) on digital assets
-
-
-182,887
-
Realized loss on digital assets
-
904,394
-
-
Fair value of shares issued for services
53,400
-
-
-
Prepaid insurance
29,349
-2,808
14,893
-6,301
Other prepaid expenses
56,244
-17,014
-26,104
2,290
Accounts payable and accrued expenses
-45,401
285,115
59,218
36,443
Research and development contract liabilities
6,297
-3,017
-20,992
21,069
Advances on research and development contract services
-
-
-
0
Operating lease liability
22,813
-
-
-
Net cash used in operating activities
-1,831,363
-1,087,898
-926,752
-1,055,968
Purchase of digital assets
-
0
2,637,360
-
Cash paid for liora investment
-
440,000
-
-
Capitalized costs for light equipment
24,859
95,102
-
-
Net cash used in investing activities
-24,859
-535,102
-2,637,360
-
Proceeds from sale of securities in registered direct offerings, net of offering costs
-
3,841,997
1,330,812
914,228
Proceeds from sale of securities in registered private placement, net of offering costs
-
0
4,178,162
-
Payment of deferred offering costs
-
-
-
10,000
Exercise of common stock warrants
-
1
45,800
-
Net cash provided by financing activities
-
3,841,998
5,564,774
904,228
Net change in cash
-
4,067,920
-
-
Net increase (decrease)
-3,705,144
-
2,000,662
-151,740
Cash - beginning of period
5,106,872
2,887,874
1,038,952
-
Cash - end of period
3,250,650
5,106,872
2,887,874
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease)
-$3,705,144
Non-cash operating lease
cost
$122,553
Stock-based compensation
expense
$82,176
Fair value of shares
issued for services
$53,400
Operating lease liability
$22,813
Research and development
contract liabilities
$6,297
something is missing
-$1,848,922
Net cash used in
operating activities
-$1,831,363
Net cash used in
investing activities
-$24,859
Canceled cashflow
$287,239
Net loss
-$1,987,608
Capitalized costs for light
equipment
$24,859
Other prepaid
expenses
$56,244
Accounts payable and
accrued expenses
-$45,401
Prepaid insurance
$29,349
Buy us a coffee
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)